{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:22:20Z","timestamp":1787458940764,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Finalizzata RF-2019-12370456"],"award-info":[{"award-number":["Ricerca Finalizzata RF-2019-12370456"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Ricerca Finalizzata RF-2019-12370456"],"award-info":[{"award-number":["Ricerca Finalizzata RF-2019-12370456"]}],"id":[{"id":"https:\/\/ror.org\/00789fa95","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","award":["BRI-2021"],"award-info":[{"award-number":["BRI-2021"]}]},{"award":["BRI-2021"],"award-info":[{"award-number":["BRI-2021"]}],"id":[{"id":"https:\/\/ror.org\/05dwj7825","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: OrganoHIPEC is a phase-II, two-stage, open-label clinical trial that investigates if cytoreductive surgery (CRS) and patient-tailored HIPEC, based on a preclinical platform using patient-derived organoids, can improve disease control in peritoneal metastases from colorectal cancer (CRC-PM). Methods: Adults with limited CRC-PM and no distant metastases were included. CRC-PM were sampled for organoid development during diagnostic laparoscopy. These organoids were used in an in vitro HIPEC model to test various drugs suitable for intraperitoneal administration. After 3\u20136 months of systemic chemotherapy, patients without progression underwent CRS\/HIPEC with personalized regimens based on organoid drug response. To detect an increase in 12-month peritoneal disease-free survival from 40% to 60%, 24 patients are needed. According to the two-stage design, if &lt;7 of 10 patients in Stage-1 remain PM-free at 12 months, the trial is terminated. Results: Forty-seven patients were enrolled. Among 31 patients with available organoid data, the most active drugs were mitomycin-C (n = 14), cisplatin\/mitomycin-C (n = 12), and low-dose (120 min) oxaliplatin (n = 4). No patient was sensitive to high-dose oxaliplatin (30 min) and cisplatin\/doxorubicin. Ten patients had a potential follow-up &gt;12 months. Peritoneal relapse occurred at 8 months in two patients, and one died of liver metastases at 7 months. Seven patients remained PM-free for &gt;12 months (median 16.4, range 12.6\u201328.4). Conclusions: A comprehensive precision approach using patient-derived organoids to guide personalized HIPEC is feasible and shows promising early results. High-dose oxaliplatin is poorly active. As 7\/10 patients achieved the endpoint of 12-month PM-free survival, Stage-1 was successfully completed. The trial is proceeding to Stage-2.<\/jats:p>","DOI":"10.3390\/cancers18162722","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:20:36Z","timestamp":1787322036000},"page":"2722","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring HIPEC with Patient-Derived Organoids in Colorectal Peritoneal Metastases: Results from the First Stage of the Prospective Phase II OrganoHIPEC Clinical Trial (Clinicaltrials.gov NCT06057298)"],"prefix":"10.3390","volume":"18","author":[{"given":"Dario","family":"Baratti","sequence":"first","affiliation":[{"name":"Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Varinelli","sequence":"additional","affiliation":[{"name":"Molecular Epigenomics Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9810","authenticated-orcid":false,"given":"Marcello","family":"Guaglio","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-277X","authenticated-orcid":false,"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-7382","authenticated-orcid":false,"given":"Tommaso","family":"Cavalleri","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5013-9037","authenticated-orcid":false,"given":"Davide","family":"Battistessa","sequence":"additional","affiliation":[{"name":"Molecular Epigenomics Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-836X","authenticated-orcid":false,"given":"Gaia","family":"Colletti","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-165X","authenticated-orcid":false,"given":"Manuela","family":"Gariboldi","sequence":"additional","affiliation":[{"name":"Molecular Epigenomics Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S1470-2045(12)70210-3","article-title":"Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: Standard of care or an experimental approach","volume":"13","author":"Sugarbaker","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Lancet Oncol. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ejso.2018.07.061","article-title":"Autopsy of an expert consensus: End of hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis","volume":"44","author":"Evrard","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","article-title":"Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis","volume":"43","author":"Leung","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"zrae017","DOI":"10.1093\/bjsopen\/zrae017","article-title":"Hyperthermic intraperitoneal chemotherapy in colorectal cancer","volume":"8","author":"Fisher","year":"2024","journal-title":"BJS Open"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yurttas, C., Hoffmann, G., Tolios, A., Haen, S.P., Schwab, M., Konigsrainer, I., K\u00f6nigsrainer, A., Beckert, S., and L\u00f6ffler, M.W. (2018). Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120567"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductivesurgery for colorectal carcinomatosis","volume":"254","author":"Quenet","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-024-03052-5","article-title":"Colorectal carcinoma peritoneal metastases-derived organoids: Results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside","volume":"43","author":"Varinelli","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/bjs.11206","article-title":"Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy","volume":"106","author":"Ubink","year":"2019","journal-title":"Br. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"mjac064","DOI":"10.1093\/jmcb\/mjac064","article-title":"Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases","volume":"14","author":"Varinelli","year":"2023","journal-title":"J. Mol. Cell Biol."},{"key":"ref_17","unstructured":"(2026, July 01). Lead Organizations: NCI Network Trial Development and Conduct, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jaquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","article-title":"A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis","volume":"18","author":"Fujii","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"Francies","year":"2015","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","article-title":"A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancer","volume":"15","author":"Stewart","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0959-8049(01)00058-2","article-title":"Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin","volume":"37","author":"Witkamp","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/cncr.10176","article-title":"Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: Phase I study","volume":"94","author":"Rossi","year":"2002","journal-title":"Cancer"},{"key":"ref_25","unstructured":"(2026, July 01). Tumori del Colon. Available online: https:\/\/www.aiom.it\/linee-guida-aiom-2024-tumori-del-colon\/."},{"key":"ref_26","unstructured":"(2026, July 01). Tumori Peritoneali Primitivi e Secondari. Available online: https:\/\/www.aiom.it\/linee-guida-aiom-2024-tumori-peritoneali-primitivi-e-secondari\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jso.21388","article-title":"Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies","volume":"100","author":"Deraco","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_31","first-page":"594","article-title":"Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score Analysis","volume":"31","author":"Tonello","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/sim.1600","article-title":"Admissible two-stage designs for phase II cancer clinical trials","volume":"23","author":"Jung","year":"2004","journal-title":"Stat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial","volume":"158","year":"2023","journal-title":"JAMA Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40170-024-00345-3","article-title":"Sulfatide imaging identifies tumor cells in colorectal cancer peritoneal metastases","volume":"12","author":"Sarcinelli","year":"2024","journal-title":"Cancer Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jso.23597","article-title":"Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"109","author":"Braam","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial","volume":"41","author":"Morton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SLA.0b013e31825704e3","article-title":"Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy","volume":"256","author":"Baratti","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1245\/s10434-007-9429-1","article-title":"Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity","volume":"14","author":"Kusamura","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1245\/s10434-014-3647-0","article-title":"Pathological response to neoadjuvant chemotherapy: A new prognosis tool for the curative management of peritoneal colorectal carcinomatosis","volume":"21","author":"Passot","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e202701","DOI":"10.1001\/jamaoncol.2020.2701","article-title":"Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases","volume":"6","author":"Rovers","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2017.03.028","article-title":"Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review","volume":"114","author":"Rovers","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1245\/s10434-016-5712-3","article-title":"The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review","volume":"24","author":"Waite","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO.2025.43.16_suppl.3505","article-title":"Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6)","volume":"43","author":"Rovers","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetic and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:14:01Z","timestamp":1787458441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":51,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162722"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162722","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}